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ABSTRACT 
Purpose: High-volume cancer centers have repeatedly been shown to have improved 
survival when compared to low volume centers, and, unfortunately, a high proportion of 
cancer patients eligible for post-operative chemotherapy following surgical resection of 
non-metastatic solid tumors never receive this therapy, even though it provides a survival 
benefit.  We hypothesized that patients who received their surgical resection at high-
volume cancer centers would be more likely to receive indicated adjuvant chemotherapy 
than patients who received their surgical resection at low volume centers. 
 
Methods: We identified gastric, non-small cell lung, and colon cancer patients in SEER-
Medicare between 2004-2012 where their final pathological staging resulted in an NCCN 
recommendation to receive adjuvant chemotherapy. Patients who received neoadjuvant 
chemotherapy were excluded, as were patients with metastatic disease at the time of 
diagnosis, and we investigated the impact of hospital volume on the likelihood that a 
patient would have a post-discharge consultation with a medical oncologist or receive 
adjuvant chemotherapy. 
 
Results: Patients with non-small cell lung and colon cancer who received their surgical 
resection at a high-volume institution were more likely (p < 0.05) to have a post-
discharge consultation with a medical oncologist, though these differences disappeared 
when important patient-level characteristics were adjusted for.  There were no differences 
in the rates of receiving adjuvant chemotherapy by surgical volume, yet increasing 
   
surgical volume was associated with improved disease specific survival (p < 0.03 for 
each disease). 
 
Discussion: Use of adjuvant chemotherapy is sub-optimal for elderly patients with 
gastric, non-small cell lung, and colon cancer, but is not affected by the surgical volume 
of their operative hospital. Survival differences between high- and low-volume hospitals 
cannot be explained by differences in use of adjuvant chemotherapy.  Further work is 
needed to identify, and correct, the reasons for sub-optimal administration of adjuvant 
chemotherapy in eligible patients. 
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INTRODUCTION 
The volume-outcome relationship in surgery is well established.  Patients who receive an 
operation at a high-volume institution, and by a high-volume surgeon, are less likely to 
experience post-operative morbidity and morality that those operated on at low volume 
institutions or by low volume providers1-6.  Of patients with post-operative complications, 
those who were operated on a high-volume center are more likely to survive than those 
who were not 7-10.  Finally, institutions that treat cancer more frequently have better 
survival than those that do not2,3,10-16, though the reasons for these survival differences 
remain poorly understood. It has also been shown that high-volume hospitals are more 
likely to sample an appropriate number of lymph nodes during surgery, allowing proper 
staging and prognostication17.  Countries that have centralized complex surgical care to a 
small number of selected hospitals have seen dramatic improvements in survival18,19. In 
contrast, the volume-outcome relationship does not hold when common procedures are 
studied20-22, suggesting that institutional familiarity with a procedure plays an important 
role in providing good patient outcomes.  
 
In the era of modern chemotherapy, surgical resection for non-metastatic solid tumors 
does not occur in isolation.  Most solid tumors are managed in a multi-disciplinary 
setting, with neoadjuvant or adjuvant chemotherapy added to surgical resection 
depending on disease – specific indications.  Unfortunately, rates of adjuvant therapy use 
remain sub-optimal23, possibly contributing to decreased survival in cancer patients.  The 
reasons for under utilization of adjuvant chemotherapy are poorly understood but include 
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post-operative complications24,25, age26,27, socioeconomic status28,29,race28-30, and 
geographic region31, and local practice patterns32. 
 
The impact of provider volume on chemotherapy utilization has not been widely 
explored.  There are suggestions that some under-utilization is driven by a lack of referral 
to medical oncology32.  While surgeons are not the physician ultimately responsible for 
prescribing adjuvant chemotherapy, they are responsible for delivering the results of the 
surgical pathology, first discussing the patient’s prognosis, and what (if any) further 
treatment the patient requires.  As a result, the surgeon’s knowledge of guidelines for 
appropriate post-operative care is paramount and could have dramatic effect on their 
patient’s post-operative course. 
 
To better understand whether surgical volume has an impact on the receipt of post-
operative adjuvant chemotherapy, we used the Surveillance, Epidemiology, and End 
Results (SEER) – Medicare database to assess the relationship between institutional 
surgical volume and administration of adjuvant chemotherapy to patients with gastric, 
non-small cell lung, and colon cancer where the National Comprehensive Cancer 
Network (NCCN) disease – specific guidelines recommended adjuvant chemotherapy. 
We hypothesized that high surgical volume was associated with more frequent 
administration of chemo and that increased delivery of adjuvant chemotherapy 
contributed to improved survival. 
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METHODS 
Data source and study population 
The primary data source for our study was the SEER cancer registry data linked with 
Medicare claims (SEER-Medicare).  This dataset is a combination of primarily collected 
cancer registry data from the NCI-sponsored Survey Epidemiology, and End Results 
survey and the linked Medicare claims for patients identified in SEER.  Clinical variables 
in the SEER registry are collected for all patients who live in a SEER-registry area or 
those patients who are part of a special population, and is subsequently merged with 
Medicare claims for all patients 65 and older, de-identified and released with patient and 
hospital level information.33 The study was deemed exempt research by the Institutional 
Review Board at Memorial Sloan Kettering Cancer Center, and the SEER-Medicare data 
were used in accordance with a Data Use Agreement from the NCI.  
 
We identified all patients aged 66 years and older diagnosed with cancer of the lung (non 
small cell), gastric, and colon (excluding rectal) who had a Medicare claim for surgical 
resection of the primary cancer site within three months of diagnosis.  Cases were 
identified using both Current Procedural Terminology codes (Lung: Segmentectomy: 
32505, 32506, 32507, 32484, 32488, 32669, lobectomy: 32480, 32663, Pneumonectomy: 
32440, 32442, 32445, 32671; Gastrectomy: 43620, 43621, 43622, 43631, 43632, 43633, 
43634; Colectomy: 44140, 44141, 44143, 44144, 44145, 44146, 44147, 44160, 44204, 
44205, 44206, 44207, 44208) and the 9th edition of the International Classification of 
Disease procedure codes (Lung: segmentectomy: 32.3, 32.30, 32.39, Lobectomy: 32.4, 
32.41, 32.49, pneumonectomy: 32.5, 32.50, 32.59; Gastrectomy: 43.5, 43.6, 43.7, 43.81, 
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43.83, 43.91, 43.99; Colectomy: 45.61, 45.62, 45.63, 45.71, 45.72, 45.73, 45.74, 45.75, 
45.76, 45.79, 45.82, 45.83, 48.61, 48.69). 
 
Study Cohort 
Patients were included if they had curative-intent surgical resection of non-metastatic 
lung, gastric, or colon cancer between 2004 and 2012, had continuous fee for service 
(Part A and B) Medicare claims throughout the study period, and had an NCCN 
indication for adjuvant chemotherapy based on their final surgical pathology and the 
disease and stage-specific guidelines from the NCCN in the year of the patient’s 
resection.  Hospital volume was estimated for individual patients as the number of organ-
specific procedures performed in the 365 days preceding and including the patient’s 
operation, and divided into terciles at the patient level.  As a result of defining hospital 
volume at the patient level, the patient-specific volume reflects their hospital’s recent 
experience at the time of each individual surgical resection.  It is therefore possible for a 
given institution to be considered high volume in one procedure (based on its volume in 
that procedure relative to the other hospitals in the dataset) and low volume in another or 
to be considered low volume for one patient in our study and high-volume for another. 
 
Patients were excluded if they had metastatic disease diagnosed prior to surgical 
resection, if they had prior or concurrent malignancies reported in SEER, if they were 
missing hospital identifiers, information on their surgical procedure or final surgical 
pathology, payment information, if they received neoadjuvant chemotherapy.  Patients 
were excluded if the NCCN recommended considering chemotherapy or another 
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treatment modality (including observation). Patients who receive Medicare because of a 
diagnosis of end stage renal disease and are younger than 66 were also excluded. 
 
Outcomes 
Medical oncology visits were identified in Medicare claims within 180 days of the 
patient’s discharge from their surgical hospitalization. Receipt of chemotherapy was also 
identified in Medicare claims (CPT codes 964xx, 96400-96549, Q0083-Q0085, J9000-
J9999, J8520-J8999; ICD9 procedure code 99.25; ICD9 diagnosis codes: V58.1, V66.2, 
V67.2) within 180 days of discharge from surgical hospitalization.  Overall and disease-
specific survival were estimated from cause-of-death information in SEER-Medicare. 
 
Guideline Concordance 
Final surgical pathology was identified in SEER and used, in conjunction with the 
appropriate NCCN guidelines, to categorize the recommended post-operative care. The 
NCCN guidelines, which provide detailed stage-specific guidelines for disease specific 
screening, workup, care, and observation, are widely regarded as authoritative cancer 
treatment guidelines. The NCCN updates its guidelines at least yearly, and more 
frequently as changes in cancer care warrant.  The NCCN classifies its recommendations 
into one of four different categories (Category 1: “Based upon high-level evidence, there 
is uniform NCCN consensus that the intervention is appropriate”, Category 2a: “Based 
upon lower-level evidence, there is uniform NCCN consensus that the intervention is 
appropriate”; Category 2b: “Based upon lower-level evidence, there is NCCN consensus 
that the intervention is appropriate”; Category 3: “Based upon any level of evidence, 
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there is major NCCN disagreement that the intervention is appropriate”). All NCCN 
guideline recommendations are category 2a unless explicitly stated otherwise; for the 
purposes of this analysis category 3 recommendations were not evaluated and all other 
recommendations were considered equally. 
 
NCCN guidelines, which are stage and disease specific, generally recommend 
observation (no adjuvant therapy), a clinical trial, consideration of adjuvant therapy or 
another treatment modality (often observation or a clinical trial), or administration of 
adjuvant therapy.  We considered all recommendations for different chemotherapy 
regimens equally, and we estimated  the percentage of patients who did not visit a 
medical oncologist post-operatively and, separately, did not receive chemotherapy.  
 
Surgical Outcomes 
We also examined early post-operative outcomes including 30-day mortality, post-
operative complications, readmissions, and emergency room visits within 30 days of 
surgery. Using a method previously described7,34 we used ICD9 codes available in claims 
data to identify post-operative acute renal failure (ICD9 code: 584) as well as cardiac 
(ICD 9 codes: 410.00–410.91) , pulmonary (ICD9 codes: 518.81, 518.4, 518.5, 518.8, 
481, 482.0–482.9, 483, 484, 485, 507.0), thromboembolic (ICD9 codes: 415.1, 451.11, 
451.19, 451.2, 451.81, 453.8), infectious (ICD9 codes: 958.3, 998.3, 998.5, 998.59, 
998.51), and bleeding complications (ICD9 codes: 530.82, 531.00–531.21, 531.40, 
531.41, 531.60, 531.61, 532.00–532.21, 532.40, 532.41, 532.60, 532.61, 533.00–533.21, 
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533.40, 533.41, 533.60, 533.61, 534.00–534.21, 534.40, 534.41, 534.60, 534.61, 535.01, 
535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 578.9, 998.1). 
 
Covariates  
Risk adjustment was performed using linear regression with robust standard errors to 
account for clustering of patients within hospitals. The covariates used for risk 
adjustment were patient age, sex, admission acuity, preoperative length of stay, 
comorbidity burden, SEER historical stage, census tract median income, marital status, 
SEER region, urban/rural residence, and year of surgery.  Comorbidity burden was 
estimated using the Charlson index based on inpatient, outpatient and provider claims in 
the year prior to cancer diagnosis 35-37. 
 
Statistical Methods 
Our primary analysis was a time-to-event Cox model, with sensitivity analyses performed 
to account for differential rates of death and hospice admission observed in the different 
cohorts as well as exclusions for hospitals with 30-day mortality greater than 9% for 
colectomies, 5.5% for lung resections, and 6% for gastrectomies. A competing risk 
regression analyzed the effect of institution volume on both post-operative appointment 
with an oncologist and receipt of chemotherapy while adjusting for patient age, sex, race, 
marital status, income quartile, SEER region, urban/rural residence, Charlson 
comorbidity score, the presence of post-operative complications, and length of stay for 
the index hospitalization. Statistical significance was defined a p < 0.05, all analyses were 
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conducted on SAS 9.2 (SAS Institute, Cary NC) or STATA 12 (StataCorp, College 
Station TX). 
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RESULTS 
The analysis included 2,431 patients who received a gastrectomy at 563 hospitals, 12,342 
patients who received a lung resection at 691 hospitals, and 9,006 who received a 
colectomy at 1,074 hospitals (Table 1: patient characteristics, Table 2: pathological 
characteristics).  Volume cutoffs for the low, medium, and high-volume hospitals differed 
by disease (Table 3). 
 
Table 1: Patient level characteristics, by disease type, for all patients in our cohort. 
 
GASTRIC 
(n = 2,431) 
COLON 
(n = 12,342) 
LUNG 
(n = 9,006) 
N % N % N % 
Age (Median, IQR) 76 (71 – 82) 77 (72 – 83) 74 (70 – 78) 
Female Sex 1099 45 7213 58 4447 49 
Married 1316 54 5960 48 5265 58 
Income 
     Quartile 1 600 25 3134 25 2263 25 
     Quartile 2 590 24 3084 25 2264 25 
     Quartile 3 644 26 3078 25 2252 25 
     Quartile 4 597 25 3046 25 2227 25 
Charlson score 
     Zero 1012 42 6315 51 2856 32 
     One 728 30 3276 27 3293 37 
     Two or More 691 28 2751 22 2857 32 
30-Day Complication 1342 55 5330 43 5165 57 
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Table 2: Disease-specific pathologic characteristics for all patients in our cohort. 
 
GASTRIC 
(n = 2,431) 
COLON 
(n = 12,342) 
LUNG 
(n = 9,006) 
N % N % N % 
T-stage 
     T1 142 6 422 3 1885 21 
     T2 339 14 999 8 2759 31 
     T3 1088 45 8574 69 4118 46 
     T4 846 35 2345 19 244 3 
Lymph Node Involvement 1710 70 12342 100 3327 37 
Grade 
     Well Diff 53 2 644 5 687 8 
     Mod Diff 634 26 7545 61 3194 35 
     Poorly Diff 1586 65 3461 28 4181 46 
     Undifferentiated 80 3 400 3 372 4 
     Unknown 78 3 292 2 572 6 
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Table 3: Disease-specific cohort sizes for patients in our cohort. 
 Low Volume Medium Volume High-volume 
Gastrectomy    
# Patients 782 845 804 
Surgical Volume 1 – 2 / year 3 – 5 / year 6 – 27 / year 
Lung Resection    
# Patients 2,978 3,060 2,968 
Surgical Volume 1 – 12 / year 13 – 30 / year 31 – 182 / year 
Colectomy    
# Patients 4,136 4,090 4,166 
Surgical Volume 1 – 20 / year 21 – 39 / year 40 – 143 / year 
 
 
Overall, patients who had surgery at high-volume hospitals for gastric and colon cancer, 
but not lung cancer, were more likely to have a post-discharge visit with a medical 
oncologist (Figure 1).  There were no differences in rates of receiving chemotherapy 
based on volume of a patient’s operative hospital (Figure 2). Following multivariate 
adjustment for important patient characteristics, patients who received their colectomy at 
high-volume institutions were more likely to have a post-discharge visit with a medical 
oncologist while patients who received their lung resection at a high-volume institution 
were less likely to have a post-discharge visit with a medical oncologist when compared 
to patients at a low or medium volume institution (Table 4). Institutional surgical volume 
did not affect the likelihood that a patient with gastric cancer would have a post-discharge 
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visit with a medical oncologist, and it did not influence the likelihood that a patient, 
regardless of disease type, would receive adjuvant chemotherapy (Table 5). 
 
Figure 1. 
Gastric: 
 
Colon: 
 
Lung: 
 
Disease – specific time incidence of post-operative oncologist visit rates for patients who 
underwent curative intent resection of Gastric, Colon, or Lung cancer in SEER-Medicare 
between 2004 – 2012. 
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Figure 2:  
Gastric: 
 
Colon: 
 
Lung: 
 
Disease – specific time to receipt of chemotherapy for patients who underwent curative 
intent resection of Gastric, Colon, or Lung cancer in SEER-Medicare between 2004 – 
2012.  
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Table 4: Adjusted impact of institutional surgical volume on the likelihood of having a 
post-discharge appointment with a medical oncologist. 
 
 Gastric Cancer  Lung Cancer  Colon Cancer 
Medium Volume HR p-value  HR p-value  HR p-value 
High-volume 1.032 0.65  1.02 0.63  1.029 0.42 
70-74 1.034 0.70  0.903 0.04  1.085 0.049 
75-79 0.892 0.10  0.929 0.05  0.955 0.15 
80+ 0.871 0.09  0.801 <.001  0.901 <.001 
Male Sex 0.525 <.001  0.595 <.001  0.544 <.001 
Non-white race 0.991 0.87  0.978 0.43  0.976 0.29 
Not married 1.072 0.29  1.062 0.15  0.911 0.008 
Marriage Unknown 0.875 0.02  0.891 <.001  0.834 <.001 
Income Quartile 2 0.861 0.42  0.952 0.51  0.903 0.08 
Income Quartile 3 0.94 0.38  1.013 0.76  1.042 0.20 
Income Quartile 4 0.949 0.44  1.048 0.28  1.038 0.32 
Midwest 0.915 0.33  1.04 0.38  1.133 0.001 
South 1.217 0.07  1.236 0.001  1.21 <.001 
West 0.967 0.76  0.897 0.05  1.121 0.07 
Non-metro Area 0.814 0.03  0.841 0.001  0.936 0.14 
Charlson Score = 1 0.748 <.001  0.922 0.05  0.869 <.001 
Charlson Score = 2+ 1.052 0.36  0.926 0.01  0.986 0.57 
Complication 0.967 0.60  0.852 <.001  0.871 <.001 
Year 0.92 0.11  0.956 0.11  0.965 0.13 
Index LOS 1.029 0.01  1.058 <.001  1.02 <.001 
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Table 5: Adjusted impact of institutional surgical volume on the likelihood of receiving 
adjuvant chemotherapy. 
 
 Gastric Cancer  Lung Cancer  Colon Cancer 
Medium Volume HR p-value  HR p-value  HR p-value 
High-volume 0.918 0.33  1.01 0.84  0.984 0.66 
70-74 0.932 0.47  0.902 0.06  0.968 0.48 
75-79 0.862 0.07  0.828 <.001  0.868 <.001 
80+ 0.564 <.001  0.522 <.001  0.593 <.001 
Male Sex 0.22 <.001  0.251 <.001  0.201 <.001 
Non-white race 0.897 0.11  0.897 0.003  0.949 0.05 
Not married 1.04 0.58  1.063 0.27  0.928 0.05 
Marriage Unknown 0.835 0.01  0.873 <.001  0.734 <.001 
Income Quartile 2 0.76 0.31  1.113 0.27  0.83 0.01 
Income Quartile 3 0.977 0.82  0.967 0.52  0.936 0.09 
Income Quartile 4 1.037 0.70  0.994 0.92  0.957 0.29 
Midwest 1.113 0.32  1.004 0.95  0.984 0.72 
South 1.251 0.10  1.011 0.90  1.066 0.30 
West 0.959 0.74  0.871 0.03  0.916 0.11 
Non-metro Area 0.941 0.54  0.832 0.004  0.887 0.006 
Charlson Score = 1 0.871 0.26  1.026 0.64  0.857 0.002 
Charlson Score = 2+ 0.948 0.47  0.931 0.07  0.884 <.001 
Complication 0.812 0.02  0.765 <.001  0.683 <.001 
Year 0.903 0.15  0.946 0.11  0.861 <.001 
Index LOS 0.971 <.001  1.042 <.001  0.963 <.001 
 
 
Sensitivity analyses performed to account for differential censoring due to either death or 
entering hospice care did not change our results, nor did excluding patients who had 
surgery at hospitals with very high 30-day mortality. 
 
We did observe statistically significant differences in post-operative survival based on 
institutional surgical volume. For all cancer types, patients undergoing surgical resection 
at high-volume centers had significantly longer disease-specific survival than patients 
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operated on elsewhere (Figure 3), and patients with either colon or lung cancer had 
significantly improved overall survival when operated on at a high-volume institution 
(Figure 4).  
 
Figure 3: 
Gastric: 
 
Colon: 
 
Lung: 
 
Disease-specific survival by hospital operative volume following curative-intent resection 
of Gastric, Colon, or Lung cancer in SEER-Medicare between 2004 – 2012.
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Figure 4:  
Gastric: 
 
Colon: 
 
Lung: 
 
Overall survival by hospital operative volume following curative-intent resection of 
Gastric, Colon, or Lung cancer in SEER-Medicare between 2004 – 2012. 
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DISCUSSION 
In this retrospective analysis of patients with advanced non-metastatic gastric, non-small 
cell lung, or colon cancer in the SEER-Medicare database who received curative-intent 
surgical resection of gastric, lung, or colon cancer between 2004 and 2012 with 
advanced, non-metastatic disease, the operative volume at the institution where they 
received their resection did not influence the likelihood that they would receive post-
operative chemotherapy.  The impact of having a post-discharge visit with a medical 
oncologist, an important precursor to receiving chemotherapy32, was more varied. Having 
surgery at a high-volume center increased the likelihood of seeing a medical oncologist in 
colon cancer patients, decreased the likelihood with lung cancer patients, and did not 
have an affect with gastric cancer.  These differences disappeared when we controlled for 
important patient-level factors known to affect the likelihood of receiving chemotherapy. 
 
We analyzed both the likelihood that a patient would have a post-discharge visit with a 
medical oncologist and the likelihood that they would receive adjuvant chemotherapy 
within six months of their surgical discharge because we felt that the surgeon’s 
responsibility is to refer that patient to a medical oncologist.  Receipt of adjuvant 
chemotherapy has repeatedly been shown to decrease recurrence and improve survival, 
yet it is under delivered25,26,28,30-32.  We excluded patients who received neoadjuvant 
chemotherapy because we were interested in whether the surgeon, post-operatively, 
would refer newly diagnosed patients to a medical oncologist. In patients who receive 
neoadjuvant chemotherapy, regardless of who made the initial referral, the therapeutic 
relationship between the medical oncologist and the patient is already established. 
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Though we did not observe differential rates of chemotherapy receipt, we did, again 
observe that patients who received their surgical resection at high-volume centers have 
improved disease-specific (for gastric, lung, and colon cancers) and overall (for lung and 
colon cancers) survival compared with patients who received their surgical resection at 
lower volume centers. Most importantly, between 40 and 60% of patients in our study did 
not receive their indicated adjuvant chemotherapy.  Omission of chemotherapy was 
associated with a number of factors, including advanced age, lower socioeconomic status, 
being unmarried, non-urban location, increased post-operative length of stay and higher 
Charlson comorbidity score (Table 5).  The difference between the rates of patients with 
a post-operative oncologist visit and the rate of patients receiving adjuvant chemotherapy 
likely represents patients who, in conjunction with their medical oncologist, elected not to 
receive chemotherapy. We could not determine the reason patients did not receive 
indicated chemotherapy.  For the patients who never saw a medical oncologist post-
operatively, we do not know whether their surgeon recommended an appointment that 
they did not keep or if that essential referral was never made. 
 
We used hospital volume instead of individual surgeon volume in order to account for the 
effect of casual patient care discussions that occur throughout the work day. It is possible, 
of course, that a surgeon may curbside consult a medical oncologist, describe a frail 
patient, and find out that the medical oncologist would never give that patient 
chemotherapy, and then the surgeon would never make that referral. Just as patients 
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should be party to decisions to administer chemotherapy they should be party to decisions 
not to administer chemotherapy. 
 
Most of the published data investigating the impact of surgeon volume has shown that 
higher volume improves outcomes.  The majority of this work, however, has been 
conducted on high-risk procedures.  When low risk procedures have been studied the data 
has shown that volume has minimal, or no, impact on post-operative morbidity and 
morality20-22.  Though we believed that the surgeon’s decision to refer a patient to a 
medical oncologist was akin to the knowledge required to safely perform a complicated 
cancer resection it is possible that it is more analogous to performing a laparoscopic 
cholecystectomy: safer and more routine although not without infrequent complications. 
 
The decision to administer chemotherapy is an important decision made by a medical 
oncologist and their patient, but we could not account for those discussions.  Though the 
NCCN recommends that all patients in our study receive disease specific chemotherapy, 
there are circumstances where as an oncologist and a patient may, appropriately, agree 
that the risks of receiving chemotherapy outweigh the potential benefit a patient may 
receive.  For this reason we also measured the rate at which patients have a post-
discharge appointment with a medical oncologist.  Even with this additional analysis we 
observe that between 20 and 30% of patients never meet a medical oncologist post-
operatively, and therefore never have the opportunity to have this discussion.  
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Though we were able to tell if patients received any chemotherapy, we were not able to 
determine whether the regimen they received was consistent with NCCN guidelines due 
to the complexity of translating individual HCPCS codes (which are drug specific) to 
NCCN-recommended adjuvant therapy guidelines for agent, dose and frequency.  We 
therefore assume, possibly erroneously, that all patients who received neoadjuvant 
chemotherapy received the correct drug regimen.  Also, we only identified initial 
adjuvant chemotherapy. We did not attempt to determine which of our patients 
experienced a disease recurrence and differences in their subsequent treatment, 
differences in which could account for the observed survival differences.  
 
Patients with advanced non-metastatic solid tumors are optimally treated with surgical 
resection and chemotherapy, both of which have independently been shown to increase 
survival. We hypothesized that the volume-outcome relationship in surgery, where high-
volume hospitals    have repeatedly been shown to out perform low volume hospitals, 
would hold true in post-discharge care.   We believed that patients treated at high-volume 
hospitals would be more likely to see a medical oncologist post-operatively, would be 
more likely to receive adjuvant chemotherapy, and that these improvements in care 
would translate to improved survival.  We found, instead, that there was no relationship 
between the volume of cancer surgery an institution performs and the likelihood that a 
patient treated at that hospital would receive adjuvant chemotherapy.  More research 
must be paid to understanding the reasons for non-adherence to adjuvant chemotherapy 
guidelines so that more effort can be paid to improving the guidelines and their 
adherence.    
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